CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF
A chimeric antigen receptor, comprising an amino acid sequence shown in SEQ ID NO. 1. A nucleic acid encoding the chimeric antigen receptor, a vector comprising the nucleic acid, an immune effector cell comprising the chimeric antigen receptor, the nucleic acid molecule and/or the vector, a method for preparing the immune effector cell, a composition comprising the immune effector cell, and use of the chimeric antigen receptor.
1 . A chimeric antigen receptor, comprising the amino acid sequence shown in SEQ ID NO. 1.
2 . An isolated nucleic acid molecule, encoding the chimeric antigen receptor according to claim 1 .
3 . An isolated nucleic acid molecule, encoding a chimeric antigen receptor, wherein the nucleic acid molecule comprises the nucleic acid sequence shown in SEQ ID NO. 2.
4 . A vector, comprising the nucleic acid molecule according to claim 2 .
5 . An immune effector cell, comprising one or more of the following:
the chimeric antigen receptor according to claim 1 ,
a nucleic acid molecule encoding the chimeric antigen receptor according to claim 1 , and
a the vector comprising the nucleic acid molecule encoding the chimeric antigen receptor according to claim 1 .
6 . The immune effector cell according to claim 5 , wherein the immune effector cell is selected from the group consisting of a T lymphocyte and a natural killer cell.
7 . The immune effector cell according to claim 5-6 , wherein the a chimeric antigen receptor comprising an amino acid sequence shown in SEQ ID NO. 1 is expressed on the surface of the cell.
8 . A method for preparing the immune effector cell, comprising the a step of transducing the vector according to claim 4 into the immune effector cell.
9 . The method according to claim 8 , wherein the immune effector cell is selected from the group consisting of a T lymphocyte and a natural killer cell.
10 . A composition, comprising the immune effector cell according to claim 5 .
11 - 18 . (canceled)
19 . A method for treating a disease or disorder associated with CD19 expression, comprising the step of administrating one or more of the following to a patient in need thereof
the chimeric antigen receptor according to claim 1 ,
a nucleic acid molecule encoding the chimeric antigen receptor according to claim 1 ,
a vector comprising the nucleic acid molecule encoding the chimeric antigen receptor according to claim 1 , and
an immune effector cell comprising one or more of the following: the chimeric antigen receptor according to claim 1 , the nucleic acid molecule encoding the chimeric antigen receptor according to claim 1 , and the vector comprising the nucleic acid molecule encoding the chimeric antigen receptor according to claim 1 .
20 . The method according to claim 19 , wherein the disease or disorder associated with CD19 expression comprises non-solid tumors.
21 . The method according to claim 20 , wherein the non-solid tumor comprises leukemia and/or lymphoma.
22 . The method according to claim 19 , wherein the disease or disorder associated with CD19 expression comprises acute lymphoblastic leukemia and/or B-cell lymphoma.
23 . The method according to claim 22 , wherein the acute lymphoblastic leukemia comprises acute lymphoblastic leukemia in adults and/or acute lymphoblastic leukemia in children.
24 . The method according to claim 23 , wherein the step of administrating is administered at a dose of 0.25 × 10 8 to 0.5 × 10 8 CAR-positive T cells.
25 . The method according to claim 22 , wherein the B-cell lymphoma comprises non-Hodgkin’s lymphoma.
26 . The method according to claim 25 , wherein the step of administrating is administered at a dose of 1 × 10 8 to 2 × 10 8 CAR-positive T cells.
27 - 34 . (canceled)
35 . The vector according to claim 4 , wherein the vector is a lentivirus vector.
36 . The composition according to claim 10 , further comprising one or more formulations of carriers, stabilizers, excipients, diluents, solubilizers, surfactants, emulsifiers and preservatives.
37 . The composition according to claim 10 , wherein the composition is present in the form of liquid, and frozen or lyophilized composition.
38 . The composition according to claim 10 , wherein the immune effector cell is selected from the group consisting of a T lymphocyte and a natural killer cell.
39 . The composition according to claim 10 , wherein a chimeric antigen receptor comprising an amino acid sequence shown in SEQ ID NO. 1 is expressed on the surface of the immune effector cell.
40 . The method according to claim 23 , wherein the acute lymphoblastic leukemia is relapsed or refractory acute lymphoblastic leukemia.
41 . The method according to claim 24 , wherein the CAR-positive T cells are administrated in a single dose.
42 . The method according to claim 24 , wherein the CAR-positive T cells are administrated by intravenous injection.
43 . The method according to claim 25 , wherein the non-Hodgkin’s lymphoma is relapsed or refractory non-Hodgkin’s lymphoma.
44 . The method according to claim 26 , wherein the CAR-positive T cells are administrated in a single dose.
45 . The method according to claim 26 , wherein the CAR-positive T cells are administrated by intravenous injection.